Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
beta thalassemia
Pharma
Long-term data shows durability of Vertex's gene therapy Casgevy
At the European Hematology Association conference, Vertex presented long-term data showing the durability and effectiveness of gene therapy Casgevy.
Kevin Dunleavy
Jun 14, 2024 11:12am
Vertex's Casgevy launch progresses as CF drugs post solid growth
May 7, 2024 11:23am
FDA approves Vertex, CRISPR's Casgevy for beta thalassemia
Jan 16, 2024 3:40pm
Agios charts broad path for oral thalassemia med after trial win
Jan 3, 2024 10:49am
In 'historic' nod, UK signs off on Vertex, CRISPR's gene therapy
Nov 16, 2023 11:45am
Vertex teases launch plans for first CRISPR gene editing therapy
Feb 8, 2023 2:55pm
